- Home
- REXR vs BBIO Comparison
REXR vs BBIO Comparison
Compare REXR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REXR
- BBIO
- Stock Information
- Founded
- REXR 2013
- BBIO 2015
- Country
- REXR United States
- BBIO United States
- Employees
- REXR N/A
- BBIO N/A
- Industry
- REXR Real Estate Investment Trusts
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- REXR Real Estate
- BBIO Health Care
- Exchange
- REXR Nasdaq
- BBIO Nasdaq
- Market Cap
- REXR 7.7B
- BBIO 6.7B
- IPO Year
- REXR 2013
- BBIO 2019
- Fundamental
- Price
- REXR $34.19
- BBIO $34.17
- Analyst Decision
- REXR Hold
- BBIO Strong Buy
- Analyst Count
- REXR 9
- BBIO 12
- Target Price
- REXR $42.33
- BBIO $57.09
- AVG Volume (30 Days)
- REXR 2.6M
- BBIO 3.1M
- Earning Date
- REXR 04-16-2025
- BBIO 04-29-2025
- Dividend Yield
- REXR 5.02%
- BBIO N/A
- EPS Growth
- REXR 12.67
- BBIO N/A
- EPS
- REXR 1.23
- BBIO N/A
- Revenue
- REXR $974,598,000.00
- BBIO $127,415,000.00
- Revenue This Year
- REXR $9.78
- BBIO $13.67
- Revenue Next Year
- REXR $10.60
- BBIO $118.02
- P/E Ratio
- REXR $27.88
- BBIO N/A
- Revenue Growth
- REXR 18.04
- BBIO N/A
- 52 Week Low
- REXR $29.68
- BBIO $21.62
- 52 Week High
- REXR $52.61
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- REXR 48.64
- BBIO 44.19
- Support Level
- REXR $33.31
- BBIO $33.92
- Resistance Level
- REXR $34.58
- BBIO $39.16
- Average True Range (ATR)
- REXR 0.81
- BBIO 1.50
- MACD
- REXR 0.36
- BBIO -0.24
- Stochastic Oscillator
- REXR 86.78
- BBIO 10.35
About REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.